Answers are grounded in this paper and cite their sources.
Genitourinary syndrome of menopause (GSM) is a chronic and highly prevalent condition encompassing vulvovaginal, sexual, and lower urinary tract symptoms that may substantially impair quality of life. Although several effective therapies are available, interest in non-hormonal strategies has increased, particularly among women who prefer to avoid hormonal treatment and breast cancer survivors. The objective of this study was to critically review the biological rationale, clinical evidence, safety, and potential therapeutic positioning of intravaginal oxygen-based interventions combined with hyaluronic acid (HA) for GSM. A narrative literature review was conducted using PubMed/MEDLINE, Embase, Scopus, and Web of Science. The included literature covered publications from 2002 to 2026, with clinical studies specifically evaluating combined intravaginal oxygen-based interventions and HA published between 2018 and 2026. Studies were selected according to their relevance to GSM, treatment characteristics, and reported clinical outcomes. Evidence was critically synthesized, considering methodological limitations and differences in oxygen-delivery protocols. Vaginal hyaluronic acid has demonstrated clinical benefits in postmenopausal vulvovaginal atrophy, whereas the additional biological contribution of locally administered oxygen remains uncertain. Proposed oxygen-related mechanisms are largely extrapolated from wound-healing research, without direct mechanistic confirmation in estrogen-deficient human vaginal tissue. Clinical studies evaluating combined intravaginal oxygen and HA have reported improvements in vaginal symptoms, vaginal health parameters, sexual function, and selected patient-reported urinary outcomes. However, oxygen-delivery protocols differ across studies, and the available comparative evidence is limited to a small controlled investigation and a retrospective non-randomized study. These findings do not establish the independent efficacy of oxygen or its effectiveness as a treatment for urinary incontinence. Short-term tolerability appears favorable, although long-term safety and treatment durability remain insufficiently investigated. Intravaginal oxygen-based interventions combined with HA represent an emerging non-hormonal approach for GSM, although current evidence remains preliminary. Adequately powered multicenter randomized trials, particularly comparisons with HA alone, are required to establish the incremental contribution of oxygen, durability of benefit, long-term safety, and appropriate positioning within GSM management.
No takes yet. Share an insight, caveat, or question.
Messina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: